Janux Therapeutics, Inc. (JANX) stock
JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3037% below fair value
$10.31−0.40 (-3.73%)
Close on Nov 18, 2026Market cap $630.32MP/E –Yield –
Janux Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Janux Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$143.56M. For fiscal 2025 it was -$157.67M. The highest annual figure on record is -$4.84M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$157.67M | – |
| FY2024 | Dec 31, 2024 | -$98.85M | – |
| FY2023 | Dec 31, 2023 | -$72.98M | – |
| FY2022 | Dec 31, 2022 | -$67.09M | – |
| FY2021 | Dec 31, 2021 | -$32.93M | – |
| FY2020 | Dec 31, 2020 | -$4.84M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$31.69M | – |
| Q1 FY2026 | Mar 31, 2026 | -$34.21M | – |
| Q4 FY2025 | Dec 31, 2025 | -$42.40M | – |
| Q3 FY2025 | Sep 30, 2025 | -$35.25M | – |
| Q2 FY2025 | Jun 30, 2025 | -$45.12M | – |
| Q1 FY2025 | Mar 31, 2025 | -$34.90M | – |
| Q4 FY2024 | Dec 31, 2024 | -$29.02M | – |
| Q3 FY2024 | Sep 30, 2024 | -$35.84M | – |
| Q2 FY2024 | Jun 30, 2024 | -$13.82M | – |
| Q1 FY2024 | Mar 31, 2024 | -$20.16M | – |
| Q4 FY2023 | Dec 31, 2023 | -$16.14M | – |
| Q3 FY2023 | Sep 30, 2023 | -$15.81M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.75M | – |
| Q1 FY2023 | Mar 31, 2023 | -$20.28M | – |
| Q4 FY2022 | Dec 31, 2022 | -$18.27M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.02M | – |
| Q2 FY2022 | Jun 30, 2022 | -$17.26M | – |
| Q1 FY2022 | Mar 31, 2022 | -$13.54M | – |
| Q4 FY2021 | Dec 31, 2021 | -$13.49M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.90M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.25M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.28M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.66M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.26M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.11M | – |
See a number that looks wrong?